Nemera launches UniSpray, a unidose system for the nasal administration of systematic-acting pharmaceuticals.

According to the company, UniSpray is a ready-to-use primeless device that delivers a single liquid dose of 100µL. This can be used by patients to self-administer remedies with rapid onset for a range of health conditions.

Nemera says UniSpray offers one-handed activation using an ergonomic finger rest, with an “intuitive” delivery method. It adds that, while easy to use, UniSpray also has a secure feature that prevents accidental activation.

The UniSpray solution is compatible with existing primary drug containers. In addition, it reportedly accelerates time-to-market as it offers possible adaptions to conventional filling lines.

Other features of UniSpray include a broad labelling surface and customisation options.

Under the Freedom to Operate assessment, Nemera claims that UniSpray is complaint with current regulations and is a reliable solution for customers. It is currently a concept under development.

Bernhard Rohn, VP of strategy and marketing at Nemera, comments: “Nemera has a long-standing experience in the nasal delivery route, focusing until now on multidose pumps.

“Adding UniSpray to our product range provides additional options for our customers and patients, answering the needs of the single-metered dose spray combination products.”

Raphaële Audibert, global category manager of ENT at Nemea, adds: “The increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy as well as growing adoption of self-administration practices are some of the key factors driving the growth of the nasal market.”

Previous innovations from Nemera include its RetroNose solution, also for nasal administration, which it says offers enhanced drug deposition results compared to classic nasal sprays.

The UniSpray will be at booth 6J42 at the CPhI Worldwide event in Milan, Italy, from the 9th to the 11th of November.